Study Title: A study of INT-747 (6-ECDCA) in combination with ursodeoxycholic acid (URSO ®, UDCA) in patients with primary biliary cirrhosis
Category: Gastroenterology
Currently accepting participants?
Not at this time.
Principal Investigator: Kris Kowdley
Study Coordinator: Cheryl Saunders
Phone: 206-341-1786
Email: Cheryl.saunders@vmmc.org
What is the A study of INT-747 (6-ECDCA) in combination with ursodeoxycholic acid (URSO ®, UDCA) in patients with primary biliary cirrhosis study?
Who can participate?
Study Summary:
Detailed Study Description:
Study Design: Blinded
Phase of Study: Phase II
Study Type: Interventional
Condition or Study Focus: Primary Biliary Cirrhosis
Intervention Type: Drug
Intervention Name: INT-747
Gender: Male and Female
Age group: Interventional
Sponsor: Intercept Pharmaceuticals
Other studies in this category include:
Studies currently accepting study participants:
No studies currently listed. Please try another category.
Studies currently not accepting study participants:
- 5-arm, parallel-group study of the effects on viral kinetics, safety and pharmacokinetics of different dosing regimens of Debio 025 in combination with peginterferon alpha-2a and ribavirin in chronic HCV genotype 1 patients who non-responders to standard
- A Phase 2b, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of GS-9450 in Adults with Chronic Hepatitis C Virus Infection
- A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease with AT-1001
- A Randomized Phase II/III of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
- A study of INT-747 (6-ECDCA) in combination with ursodeoxycholic acid (URSO ®, UDCA) in patients with primary biliary cirrhosis
- A Study of INT-747 Monotherapy in Patients with Primary Biliary Cirrhosis
- Abatacept in Treatment of Patient with Active Crohns Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
- Abatacept in Treatment of Patient with Active Ulcerative Colitis (UC) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
- Boceprevir in Subjects with Previously Untreated Chronic HCV Genotype 1
- Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy
- RG1068 (Synthetic Human Secretin) – Enhanced MRCP in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis